---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Long-term morbidity"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Long-term morbidity. Topics: Metastatic uveal melanoma as the leading cause of death; Liver deterioration before death in metastatic disease; Disability attributed to the condition: vision impairment, enucleation, pain, and organ failure; Metastatic sites at death, COMS large tumor trial; 9 further topics. 13 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Metastatic uveal melanoma as the leading cause of death

> “The audited cause of death was uveal melanoma in 145 (61%) of them.”
> “Metastatic uveal melanoma was the leading single cause of death throughout the study.”

Source: [Kujala et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14578381/)

<a id="topic-2.2.1.7-2"></a>

### Liver deterioration before death in metastatic disease

> “Patients with metastatic UM develop late symptoms leading to rapid deterioration in the liver and overall QoL before death.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.7-3"></a>

### Disability attributed to the condition: vision impairment, enucleation, pain, and organ failure

> “the condition is life-threatening with a reduced survival in relapsed/refractory metastatic disease and chronically debilitating due to vision impairment (enucleation of the affected eye) and pain;”
> “The COMP concluded that the condition is life-threatening with a reduced survival in relapsed/refractory disease and chronically debilitating especially due to enucleation and in metastatic disease due to pain, organ failure, and treatment burden.”

Source: [European Medicines Agency KIMMTRAK orphan maintenance assessment report (2022)](https://www.ema.europa.eu/documents/orphan-maintenance-report/kimmtrak-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

<a id="topic-2.2.1.7-4"></a>

### Metastatic sites at death, COMS large tumor trial

> “A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sites were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis.”

Source: [Collaborative Ocular Melanoma Study Group (2001)](https://pubmed.ncbi.nlm.nih.gov/11346394/)

<a id="topic-2.2.1.7-5"></a>

### Hepatic and extrahepatic metastatic sites during follow-up

> “Liver was the most common site (89%).”

Source: [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/)

> “Systemic metastases are generally hematogenous in origin, and the first site identified is usually the liver.”
> “Lung, bone, and subcutaneous sites are also common.”
> “In the COMS trials, the liver was the only site of detectable metastasis in 46% of patients with metastases reported during follow-up or at the time of death; 43% had metastases diagnosed in the liver and other sites.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “The liver was the most affected site: 88% of patients having liver metastases. Other affected sites were the lungs (25.1%), lymph nodes (16%) and bones (15.4%)”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Ninety-two percent of patients had hepatic metastases with or without dissemination to other sites, and 70% had only hepatic metastases”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.7-6"></a>

### Survival after symptomatic brain metastases

> “Following diagnosis of symptomatic BM, mOS was 7.6 months”

Source: [Wei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540230/)

<a id="topic-2.2.1.7-7"></a>

### Second primary malignancies

> “27.4% of patients had another primary malignancy”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.7-8"></a>

### Primary tumor treatment: surgery and radiation trends, 1975 to 2020

> “The previously reported declining trend in the number of patients treated with surgery alone (93% from 1975 to 1977 vs. 21% from 2017 to 2020) ensued, with ongoing corresponding increasing rates of radiation as the primary treatment (1% from 1975 to 1977 vs. 58% from 2017 to 2020).”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.7-9"></a>

### Enucleation of the affected eye

> “A tumour with an extensive extraocular extension or that replaces >50% of the globe or leads to a blind and/or painful eye should be treated with enucleation or exenteration (30% of patients).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.7-10"></a>

### Radiation-related ocular complications: maculopathy, optic neuropathy, neovascular glaucoma, and cataract

> “Any type of RT can lead to posterior complications such as maculopathy, optic neuropathy, neovascular glaucoma and retinopathy, which can have an impact on vision and eye preservation.”
> “In the anterior segment of the eye, cataract and dry eye are the most common side-effects.”
> “Signs of RT-induced maculopathy on fundus examination are detected in ≤66.5% of cases within 3 years of PBR.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.7-11"></a>

### Visual acuity after iodine-125 brachytherapy, COMS medium tumor trial

> “Three years after I(125) brachytherapy, median visual acuity was 20/125, with 34% having 20/40 or better and 45% having 20/200 or worse visual acuity, including eyes that were enucleated within 3 years of treatment.”

Source: [Melia et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11158813/)

> “Eighty-five percent of the patients treated with 125I brachytherapy retained their eye for 5 years or more, and 37% of them had visual acuity better than 20/200 in the irradiated eye 5 years after treatment.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.7-12"></a>

### Psychological morbidity: anxiety, depression, and worry about recurrence after prognostic testing

> “Compared to other groups, survivors with poor prognoses showed initially elevated anxiety and depression and consistently elevated worry about local or distant recurrence over 5 years.”

Source: [Brown et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8964647/)

> “The mean (SD) HADS anxiety score at baseline (7.4 [4.0]) was higher than at 3 months (5.4 [3.7]; P < .001) or 12 months (4.7 [3.4]; P < .001), and decreased with older age (coefficient estimate [SD], -0.06 [0.02]; P < .001).”

Source: [Schuermeyer et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26539659/)

<a id="topic-2.2.1.7-13"></a>

### Psychological burden of surveillance and of eye loss

> “The discussion should include the emotional and organisational impact of this surveillance strategy as well as its frequency and duration.”
> “QoL is affected by specific concerns, including recurrence and loss of the eye or visual impairment. These need to be considered by ophthalmologists and oncologists, who should provide appropriate care, including psychological support, as depressive symptoms are common after ocular tumour treatment.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
